They are taken valtrex use by mouth. "How Common is Valtrex use genital Herpes?" Genital Herpes. The Food and Drug Administration has approved valacyclovir for use as suppressive therapy to reduce the risk of heterosexual transmission of genital herpes to susceptible partners. Overall, less than two percent of pregnant women with HSV acquired the virus during their pregnancy. 27, 2001 Flamel Technologies S. However, there is no scientific proof that these valtrex use natural therapies work, and experts caution that topical treatment of sores appears to have no added benefit when used in conjunction with antiviral drugs. Hunter Handsfield, professor of medicine at the University of Washington, Seattle, said valtrex use in an interview. Treating women who develop genital herpes during pregnancy is critical to protecting newborns from acquiring the virus. If an infant is infected, antiviral medication can greatly improve the outcome, particularly if valtrex use treatment starts immediately. With early detection and treatment, most of the serious complications of neonatal herpes can be lessened. GlaxoSmithKline is one of the world’s leading research-based pharmaceutical and health valtrex use care companies. Valtrex also may help herpes sufferers reduce their own chances of becoming infected with HIV and human papillomavirus by preventing the open lesions through which viruses can easily enter the body. Flamel’s expertise in polymer science has also been instrumental in Valtrex use the development of a photochromic eyeglass lens product now marketed by Corning Inc. "Episodic therapy" is taken at the first appearance of symptoms. When asymptomatic infections were included, the risk of transmission decreased by 50%, which was still a significant reduction. Half of the babies infected with herpes either die or valtrex use suffer neurologic damage. Valtrex, also known as valacyclovir, treats herpes flare-ups by suppressing the virus Business Editors LYON, France–(BUSINESS WIRE)–Sept. (NASDAQ:FLML) announced today that it has received notification from the French Pharmaceutical Regulatory Agency that Flamel’s controlled-release acyclovir product, Genvir(R), which was filed for approval in August, 2000, has been refused regulatory approval pending valtrex use a second study which would compare Genvir(R) to valacylovir. Available since 1995, valacyclovir (Valtrex) was previously approved for the treatment or suppression of genital herpes in otherwise healthy people and suppression of recurrent genital herpes in HIV-infected individuals.